SpeeDx is a technology company.
SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
SpeeDx has raised $30.0M across 2 funding rounds.
SpeeDx has raised $30.0M in total across 2 funding rounds.
SpeeDx has raised $30.0M in total across 2 funding rounds.
SpeeDx's investors include Northpond Ventures, Section 32.
SpeeDx is an Australian molecular diagnostics company developing advanced multiplex PCR tests for infectious diseases, powered by proprietary PlexPCR®, PlexPrime®, and PlexZyme® technologies.[1][2] It serves clinical laboratories, healthcare networks, and researchers by simplifying diagnostics through multi-target testing in single reactions, combining pathogen detection with antibiotic resistance markers to guide treatment and streamline workflows.[1][2] The company addresses key challenges in patient management by providing comprehensive, actionable data from fewer samples, with offices in Sydney, London, and Austin supporting global expansion and rapid growth.[2]
SpeeDx emerged as an innovator in molecular diagnostics, building on proprietary technologies like PlexPrime®—a novel nucleic acid amplification method—and PlexZyme® for high-specificity multiplex detection.[1] While exact founding details are not specified in available sources, the company has evolved into a dynamic, rapidly growing entity with a strong portfolio of cutting-edge diagnostic tools, earning awards and grants for its multiplex innovations.[2] Pivotal moments include global office expansions and collaborations with researchers and clinicians to address urgent clinical needs, such as antibiotic resistance testing via ResistancePlus® assays.[1][2]
SpeeDx rides the wave of precision medicine and antimicrobial resistance trends, where multiplex molecular diagnostics are critical for faster, more accurate infectious disease testing amid rising global health threats.[1][2] Timing aligns with post-pandemic demand for efficient lab tools that conserve resources and inform therapies, bolstered by market forces like regulatory support and grants for innovative diagnostics.[2] It influences the ecosystem by enabling collaborations, advancing research publications, and integrating into healthcare networks, ultimately accelerating clinically relevant data generation worldwide.[2]
SpeeDx is poised for continued expansion through new product launches, deeper global partnerships, and leveraging its tech for emerging resistance challenges and broader multiplex applications.[2] Trends like AI-enhanced diagnostics and point-of-care testing could amplify its edge, evolving its role from specialist innovator to key player in personalized healthcare. As molecular tools become standard, SpeeDx's focus on actionable insights positions it to drive efficiency in overburdened labs, tying back to its core strength in simplifying complex diagnostics for real-world impact.[1][2]
SpeeDx has raised $30.0M across 2 funding rounds. Most recently, it raised $15.0M Series B in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $15.0M Series B | Northpond Ventures, Section 32 | |
| Aug 1, 2019 | $15.0M Series A | Northpond Ventures, Section 32 |